Tiziana responds to uk call for development of innovative ‘take home' treatments for covid-19 disease

New york and london, june 17, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the united kingdom covid therapeutics advisory panel (uk-ctap) to support further clinical development of nasally administered foralumab, a fully human anti-cd3 monoclonal antibody, as an innovative ‘ take home' approach for treatment of non-hospitalized patients with covid-19. this is in response to a call from the uk government for proposals to study therapies that can be delivered at home and avoid hospitalization of patients.
TLSA Ratings Summary
TLSA Quant Ranking